Kayentis

Kayentis

Private
MeylanHealthcare & Life Scienceshttps://kayentis.com

Last Round

VC Round

Mar 28, 2023

Total Funding Raised

$19.85M

Company Overview

Kayentis is a healthtech company that provides electronic Clinical Outcome Assessment (eCOA) and Decentralized Clinical Trial (DCT) solutions for the collection of clinical trial data from patients and sites.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Patient Engagement, Vertical SaaS

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Hardware + Subscription

AI Layer

Non-AI

Keywords

eCOAelectronic Clinical Outcome AssessmentDecentralized Clinical TrialsDCTePROelectronic Patient-Reported Outcomesclinical trial softwareeClinical solutionsclinical trial data collectioneClinROelectronic Clinician-Reported Outcomeshybrid clinical trialsBYODBring Your Own Devicevirtual clinical trialseDiariesWebCOAeObsROeConsent integration

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kayentis Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kayentis Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 28, 2023
DebtMar 28, 2023
Growth EquityDec 2, 2020
Growth EquityOct 13, 2016
VC RoundFeb 1, 2015
Series C
Sep 1, 2007

Key People

Founding team and executive leadership

Eric ROETS

Chief Technology Officer

Executive Team

Cécile Rassele

Deputy COO

Executive Team

Kayentis Investors

Notable investors and investment history

InvestorRounds
BpifranceGrowth Equity, VC Round
Innovation CapitalGrowth Equity
ExtensGrowth Equity, VC Round
LBO FranceVC Round, Growth Equity
Seventure PartnersSeries C, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2025

    Opened new office in Tokyo, adding to Grenoble and Boston locations.

  • Jan 1, 2025

    Supported over 350 trials for 150,000+ patients in 90 countries.

Kayentis Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kayentis Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kayentis's valuation, stock price, and market status.

Firmographic Details

HeadquartersMeylan
Employee Range166
Year Founded2003
Last FundingMar 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.